Scientific Advisory Board (SAB) will provide guidance on the Company’s development strategy and advise on emerging technologies and new targets in the DNA Damage Response (DDR) field.
Edinburgh, UK – 10/11/22 – Nodus Oncology, an emerging biotech company which is focused on developing first and best-in-class molecules inhibiting novel DDR targets, announces the establishment of its SAB. Comprised of academic and industry experts in oncology drug development and DDR, the SAB will be chaired by Nodus’ scientific founder. The SAB will work cohesively with management to advance the company’s drug development pipeline and assess new technologies available.
“We are delighted to welcome such a strong advisory panel” said Ian Waddell, CEO of Nodus Oncology. “The insights and recommendations of our SAB members will be instrumental in developing the assets already in Nodus’ pipeline and expanding it through addition of innovative targets and developing use of novel technologies”.
This newly formed advisory board includes the following scientific and preclinical experts:
- Dominic James, PhD., FRSB. Dominic is currently VP of Translational Science at Imagen Therapeutics. Dominic has over 30 years’ experience in molecular and cellular biology with roles at the European Molecular Biology Laboratory, University of Geneva, AstraZeneca and the Cancer Research UK Manchester Institute. He has successfully led drug discovery projects for CRUK MI from target identification through to licencing. Dominic is an enthusiastic and highly skilled scientist who was recently elected as a Fellow to the Royal Society of Biology.
- Marcel Van vugt, PhD. Is Professor of Molecular Oncology at the Department of Medical Oncology at the University of Groningen, The Netherlands. Marcel’s interest in the DDR started during his PhD at the Netherlands Cancer Institute in Amsterdam, under supervision of Prof. Rene Medema, where he studied Cell Cycle regulation by Polo-like kinase-1. This interest continued during his postdoctoral fellowship, where Marcel studied the regulation of the DNA damage checkpoint by cell cycle kinases in the laboratory of Michael B. Yaffe at the David H. Koch, at the institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT, Cambridge USA). In 2009, Marcel started an independent research group at the University of Groningen where his research focuses on how normal cells and cancer cells deal with DNA damage, and how this knowledge can be used to improve cancer therapy. Since April 2018, Marcel is appointed Full Professor of Molecular Oncology, and since November 2018 he is director of the Cancer Research Center Groningen.
